These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 19374459)

  • 1. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease.
    Bassil N; Grossberg GT
    CNS Drugs; 2009; 23(4):293-307. PubMed ID: 19374459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal Drug Delivery Systems and their Potential in Alzheimer's Disease Management.
    Siafaka PI; Bülbül EÖ; Mutlu G; Okur ME; Karantas ID; Okur NÜ
    CNS Neurol Disord Drug Targets; 2020; 19(5):360-373. PubMed ID: 32552655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A; Svensson AL
    Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy for Alzheimer's disease.
    Patel L; Grossberg GT
    Drugs Aging; 2011 Jul; 28(7):539-46. PubMed ID: 21721598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease.
    Calhoun A; King C; Khoury R; Grossberg GT
    Expert Opin Pharmacother; 2018 Oct; 19(15):1711-1717. PubMed ID: 30244611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world evaluation of compliance and preference in Alzheimer's disease treatment.
    Pai MC; Aref H; Bassil N; Kandiah N; Lee JH; Srinivasan AV; diTommaso S; Yuksel O
    Clin Interv Aging; 2015; 10():1779-87. PubMed ID: 26622172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What are the treatment options for patients with severe Alzheimer's disease?
    Voisin T; Reynish E; Portet F; Feldman H; Vellas B
    CNS Drugs; 2004; 18(9):575-83. PubMed ID: 15222774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging pharmacological treatment options for dementia.
    Ringman JM; Cummings JL
    Behav Neurol; 2006; 17(1):5-16. PubMed ID: 16720956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease: early diagnosis and treatment.
    Chu LW
    Hong Kong Med J; 2012 Jun; 18(3):228-37. PubMed ID: 22665688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
    Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
    Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medical treatment of Alzheimer's disease].
    Johannsen P
    Ugeskr Laeger; 2006 Oct; 168(40):3424-9. PubMed ID: 17032609
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.